Volume 178 - Issue 8
Thalidomide and cancer?
Author: J Mark Elwood
Med J Aust 2003; 178 (8): 413. || doi: 10.5694/j.1326-5377.2003.tb05267.x
Published online: 21 April 2003
Published online: 21 April 2003
To the Editor: McBride reports that there were four deaths from cancer before the age of 40 years in a group of 480 thalidomide-affected people in the United Kingdom, an approximate cumulative mortality rate of 0.83%.1 He compares this with the annual death rate in the under-40-years age group, and concludes that the rate is increased almost 100 times in those affected by thalidomide.
The correct comparison is with the cumulative mortality rate in the general population from birth to age 40. From 1999 UK statistics,2 this is about 0.31% — that is, we would expect 1.48 deaths among 480 people. While the observed number of four is greater than this, it is only slightly greater, and the difference is not statistically significant (the mortality ratio is 2.7, with exact 95% confidence limits of 0.7 to 6.9, based on a Poisson distribution). McBride's conclusion is based on an inappropriate comparison.
A full analysis would use population death rates over the 40-year period and take account of censoring, but that is unlikely to affect the result substantially.
References
- McBride W. Thalidomide and cancer [letter]. Med J Aust 2002; 177; 278.<eMJA full text>
- Quinn M, Babb P, Brock A, et al. Cancer trends in England and Wales 1950–1999. London: The Stationary Office, 2001. i1082450
Uneven Ground: Survival Differences Among Victorian Lung Cancer Patients by Location of Residence (2011–2023): A Retrospective Cohort Study
Evangeline Samuel, Eldho Paul, Mike Lloyd, Sanuki Tissera, Craig Underhill, Sagun Parakh, Phillip Parente, Inger Olesen, Javier Torres, Katharine See, Gavin M. Wright, David Langton, Thomas John, Matthew Conron, James Bartlett, Nicola Atkin, Nikolajs Zeps, Susan V. Harden, Wasek Faisal, John R. Zalcberg, Rob G. Stirling
Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning
Savio G. Barreto, Christos S. Karapetis, Shahid Ullah, Matthew Burge, Susan Caird, Angus Campbell, Azim Jalali, Ross Jennens, Muhammad A. Khattak, Belinda Lee, Stephanie H. Lim, Shehara Mendis, Louise Nott, Timothy J. Price, Jeremy D. Shapiro, Jeanne Tie, Javier Torres, Colin Williams, Rachel Wong, Vanessa Wong, Peter Gibbs
Australian Pathways for Specialist Pain Management and Early Palliative Care for People With Pancreatic Cancer: Developed Using a Community Consensus Approach
Jennifer Philip, Melanie R. Lovell, Kylee Bellingham, Gail Garvey, Gregory B. Crawford, Nicole M. Rankin, Kara Burns, Isabel Young, Vivienne Milch, Dorothy Keefe, Katrina Anderson, James Lawson, Meinir Krishnasamy
Program Guidelines for the National Lung Cancer Screening Program: Targeted Lung Cancer Screening in High-Risk Individuals in Australia
Nicole M. Rankin, Rebecca Zosel, Lisa J. Whop, Raglan Maddox, Annette McWilliams, Miranda Siemienowicz, Jon Emery, Maria A. R. Lantin, Georgia Bartlett, Mikayla Wolfe, Abbey Diaz, Katrina Anderson, Lillian Liu, Cindy Toms, Sarah McDermott, Peter Bligh, Jeremy Chalke, Stephen Melsom, Claire E. Nightingale, Alison Brown, Sam Pope, Julia Brotherton, Anne Fidler, Michel Itel, Mark Brooke, Diane M. Pascoe, Fraser Brims, Tracy L. Leong, Emily Stone, Dorothy Keefe, Vivienne Milch
Beyond Mammography: Sovereignty and Relational Breast Care With Aboriginal and Torres Strait Islander Women
Devaleena Das, Jessica Gildersleeve, Amy Thomson, Aunty Gracelyn Smallwood, Lorelle Holland
Striving for Racial Equity in Oral Cancer Research: A Case Study
Sneha Sethi, Simon Naylor, Catherine Leane (Dharug/Gabrigal), Gail Garvey (Kamilaroi), Joanne Hedges (Yamatji), Lisa M. Jamieson, Nicolas Reid (Dharug/Gabrigal)